Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients

NCT00174629 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00174629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00174629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2001
Completion date
Not reported
Enrollment
449 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms